Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Albiglutide

Safety and Efficacy Study of Albiglutide in Type 2 Diabetes

GSK · Phase 3 · Completed · Enrollment 309

NCT00849017

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
albiglutiden/rn/rn/rn/r
placebon/rn/rn/rn/r
albiglutide up-titrationn/rn/rn/rn/r

Not shown

  • albiglutide: endpoint not reported
  • placebo: endpoint not reported
  • albiglutide up-titration: endpoint not reported